Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNSI-Fe(II) Dose Escalation in Advanced Solid Tumors
NCT06048367Phase 1Completed
- Sponsor
- Sichuan Enray Pharmaceutical Sciences Company
- Start
- Nov 2022
- Primary completion
- Sep 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CNSI-Fe in solid tumor (advanced stage), colorectal cancer (CRC), pancreatic cancer (PC) and 11 more (5 arms), sponsored by Sichuan Enray Pharmaceutical Sciences Company. Primary endpoint: Safety and Tolerability Assessment of CNSI-Fe(II) at 21 days. Started Nov 2022; status: completed.
02
Drugs
CNSI-Fe
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)pancreatic cancer (PC)breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT06048367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048367.